Summary Slide.png (109.08 kB)

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China

figure

posted on 2021-06-03, 13:43 authored by Adis Journals on behalf of, Ting Zhou, Yanan Sheng, Haijing Guan

Article full text

The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).

History

References

https://link.springer.com/article/10.1007/s12325-021-01806-7

Usage metrics

Read the peer-reviewed publication

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China

Advances in Therapy

Keywords

China Conventional therapy Cost-effectiveness analysis Crohn’s disease Vedolizumab

Licence

CC BY-NC 4.0

Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China

History

References

Usage metrics

Read the peer-reviewed publication

Categories

Keywords

Licence

Exports